SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-21-000032
Filing Date
2021-07-29
Accepted
2021-07-29 16:04:04
Documents
14
Period of Report
2021-07-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20210729.htm   iXBRL 8-K 41863
2 EX-99.1 a2021q2_8-kxex991.htm EX-99.1 184025
6 GRAPHIC imagea.jpg GRAPHIC 12958
  Complete submission text file 0001438533-21-000032.txt   403667

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20210729.xsd EX-101.SCH 1971
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20210729_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20210729_pre.xml EX-101.PRE 13113
7 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20210729_htm.xml XML 11208
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 211127357
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences